Weight Regain After Stopping Semaglutide: What Trials Show and How to Plan for It

With generic semaglutide far cheaper in India since the patent expired on 20 March 2026, many people are starting treatment with a fixed budget or an end date already in mind. That turns the question of what happens afterwards into a practical one.

Do people regain weight after stopping semaglutide?

Yes, most people regain a large part of it within a year. In the STEP 1 trial extension, published in 2022, adults who had lost an average of 17.3 per cent of their body weight over 68 weeks on semaglutide 2.4 mg regained 11.6 percentage points in the year after the medicine and the trial's lifestyle support both ended. That left them 5.6 per cent below their starting weight at week 120, so roughly two-thirds of the loss had come back. The averages hide wide variation: some people held on to most of their loss, others returned to where they began. Anyone planning to stop should still treat regain as the default outcome rather than the exception.

What the STEP 1 extension actually measured

The details matter before drawing lessons from it. The extension followed 327 people from sites in Canada, Germany, the UK, the United States and Japan, a subset of the 1,961 people recruited to the main trial, and its analyses were exploratory. At week 68 the medicine and the structured lifestyle programme stopped together, so the study cannot separate the loss of the drug from the loss of the counselling. Nobody tapered the dose, and there was no planned maintenance diet. It describes what happens after an abrupt, unsupported stop, which resembles what happens when someone simply runs out of money or supply, but it does not test a careful exit.

Is stopping slowly any better than stopping at once?

Nobody knows yet, because the large trials stopped the medicine abruptly. Some doctors taper to a lower dose or lengthen the gap between injections, but there is no randomised evidence that a slow exit prevents regain. What the trials do show is that the appetite effect fades as the drug leaves the body, so any benefit from tapering would depend on how well eating habits hold as hunger comes back. Decisions about tapering, a lower maintenance dose or restarting belong to the prescribing doctor. The work of preparing for returning hunger, however, can begin months before the final injection.

Does tirzepatide behave the same way?

Yes, the pattern is just as clear. In the SURMOUNT-4 trial, 670 adults who had lost an average of 20.9 per cent of their weight during a 36-week open-label lead-in on tirzepatide were randomised to continue it or switch to placebo for 52 weeks. Those who continued lost a further 5.5 per cent; those on placebo regained 14.0 per cent. The earlier STEP 4 trial found the same with semaglutide: after a 20-week run-in with an average loss of 10.6 per cent, people who stayed on the medicine lost another 7.9 per cent over 48 weeks, while those switched to placebo gained 6.9 per cent. Different medicines and designs gave one message.

Why does the weight come back?

Because the drug was holding down an appetite the body still wants to restore. GLP-1 medicines work on hunger and fullness signals, and when they wash out those signals return, now in a smaller body that is primed to regain. A 2011 study in the New England Journal of Medicine followed 50 people after a 10-week very-low-energy diet that removed 13.5 kg on average, and found that hormones encouraging eating, along with hunger ratings, had not returned to their earlier levels a year later. Energy needs also fall as the body shrinks, so the portions that once maintained the old weight now produce gain. Regain is physiology, not a moral failing.

Do the blood sugar and blood pressure gains fade too?

Largely, yes. In the STEP 1 extension, most of the cardiometabolic improvements seen at week 68 drifted back towards baseline by week 120 for the majority of markers measured, in step with the returning weight. That matters for anyone who began the medicine because of prediabetes, fatty liver or raised blood pressure rather than appearance alone. It also means an exit should come with a plan to recheck those numbers a few months later. People with type 2 diabetes need particular care, because stopping can raise glucose and other diabetes medicines may need adjusting, which is the treating doctor's decision and not something to work out at home.

How many people stop GLP-1 medicines within a year?

Most people using them for weight alone stop within a year, at least in American data. A 2025 analysis of health records for 125,474 US adults found that 64.8 per cent of those without type 2 diabetes discontinued within a year, compared with 46.5 per cent of those with diabetes. Moderate or severe stomach side effects made stopping more likely, and greater weight loss made it less likely. Comparable Indian figures do not exist yet, and local prices have fallen, but cost, supply, side effects and simple fatigue with weekly injections apply here too. The realistic assumption is that most people will stop at some point, planned or not.

Does exercise help keep the weight off?

It helps, and it seems to help most once the medicine is gone. In a Copenhagen trial published in 2021, 195 adults lost an average of 13.1 kg on an eight-week low-calorie diet and were then assigned to a year of supervised exercise, liraglutide, both combined, or placebo; the combination maintained the loss best. A follow-up a year after all treatment ended, attended by 109 participants, found that regain after stopping liraglutide alone was 6.0 kg greater than after stopping supervised exercise. Liraglutide is an older daily GLP-1 medicine, so the figures do not transfer neatly to semaglutide, but the lesson holds: habits built during treatment outlast the prescription.

Is it a failure to need the medicine long term?

No. Obesity behaves like other chronic conditions such as high blood pressure, where a medicine controls the problem while it is being taken, and the STEP 1 extension authors concluded that ongoing treatment appears necessary to keep the improvements. Some people will decide with their doctor to continue on a dose that suits them; others will want or need to stop. Neither choice says anything about character. What deserves scrutiny is stopping without any plan, or starting a three-month course in the hope that it permanently resets the body's weight, which none of the trials gives any reason to expect.

What to build while you are still on the medicine

The months on treatment are the best time to rehearse maintenance, because hunger is quiet and new routines are easier to lay down. Long-term maintainers in the US National Weight Control Registry, described in a 2005 review, shared a small set of behaviours: high levels of physical activity, a consistent eating pattern across weekdays and weekends, eating breakfast, weighing themselves regularly and catching small regains early. Four translate directly to Indian life: a fixed meal structure, a protein source at every meal, walking or strength work most days, and a weekly weigh-in. Protein and resistance training also protect muscle, which the guide to muscle loss on GLP-1 medicines explains.

How should you eat in the months after the last injection?

Eat as if hunger is coming back, because it is. Set three meals and one or two snacks at fixed times, so that returning appetite meets a structure instead of an open fridge. Keep protein and fibre high at each meal, since both make a smaller energy intake easier to live with: a katori of dal or chana, curd, paneer, eggs, fish or chicken, plus a generous serving of vegetables. Hold rice and roti at the portions that worked during treatment rather than drifting back to old helpings. Watch drinks that add energy without fullness, such as sweetened tea, packaged juice and sherbet. A calorie calculator gives a rough maintenance figure for the new, lower weight.

What does a maintenance day look like on an Indian plate?

A workable maintenance day looks ordinary, and that is the point. For a vegetarian office worker it might be a besan chilla with curd at breakfast, two phulkas with a katori of rajma, a sabzi and salad at lunch, roasted chana with tea in the late afternoon, and a dinner of a katori of rice with dal, palak paneer and cucumber raita. A non-vegetarian version swaps in eggs at breakfast and fish curry at dinner. Exact portions depend on body size, sex and activity, so the plate should be fitted by someone able to assess them. For eating while treatment continues, see the guide to the diet on semaglutide.

Which early signs of regain should prompt a review?

A steady upward trend over three or four weekly weigh-ins is the clearest signal, far more than any single reading. Body weight can swing by a kilo or more from day to day with salt, water and bowel habits, so one high number means little on its own. Other early signs are evening grazing returning, portions creeping back towards their old size, and a waist measurement that keeps rising. Agree a trigger point in advance with the doctor and whoever supports your eating, so a review happens automatically instead of after the whole loss has returned. Whether to restart a medicine is a medical decision; tightening the eating plan can begin that same week.

Planning the stop with a doctor and a coach

The best exits are planned jointly. The prescribing doctor decides the timing, any tapering and the follow-up tests, while a nutrition professional or trained coach builds the eating structure and checks in weekly as appetite returns. That coaching is skilled work: reading hunger cues, adjusting portions without triggering a crash diet, and recognising when regain or low mood needs the doctor. NNWA's Weight Loss Coach course trains coaches in this behaviour-change side of weight management, and NNWA's faculty include Sandeep Ojha, a registered pharmacist with an M.Pharm in pharmacology who understands what these medicines do in the body. People wanting support for themselves can book a consultation at the NNWA clinic, which works alongside the prescriber and does not alter medicines.

The short version

After stopping semaglutide or tirzepatide, most people regain a large share of their lost weight within a year, and their health markers follow. The trials showing this stopped the medicine abruptly and without support, so a planned exit may fare better, though that has not been properly tested. Use the months on treatment to build structure, protein, activity and a weekly weigh-in, eat for returning hunger after the final dose, and agree in advance when regain will trigger a review. For the medicines available in India and who they suit, read the overview of weight loss medicines in India.

Research this article draws on

Wilding et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. Among 327 participants followed for a year after semaglutide and lifestyle support ended, two-thirds of the lost weight returned and most cardiometabolic improvements moved back towards baseline.

Rubino et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. STEP 4: after a 20-week semaglutide run-in, those who continued lost a further 7.9 per cent over 48 weeks while those switched to placebo regained 6.9 per cent.

Aronne et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. SURMOUNT-4: after a 20.9 per cent loss over a 36-week tirzepatide lead-in, switching to placebo led to a 14.0 per cent regain over 52 weeks, while continuing added a further 5.5 per cent loss.

Sumithran et al. (2011). Long-Term Persistence of Hormonal Adaptations to Weight Loss. New England Journal of Medicine. A year after diet-induced weight loss, appetite-regulating hormones and hunger ratings had not returned to pre-diet levels, a lasting biological push towards regain.

Lundgren et al. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. After an eight-week low-calorie diet, a year of liraglutide combined with supervised exercise maintained weight loss and body composition better than either alone or placebo.

Jensen et al. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. eClinicalMedicine. One year after treatment ended, regain was 6.0 kg larger after stopping liraglutide alone than after stopping supervised exercise, suggesting exercise habits sustain loss beyond the medicine.

Rodriguez et al. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. Of 125,474 US adults starting GLP-1 medicines, 64.8 per cent without type 2 diabetes stopped within a year; stomach side effects raised, and larger weight loss lowered, the chance of stopping.

Wing and Phelan (2005). Long-term weight loss maintenance. The American Journal of Clinical Nutrition. Drawing on the National Weight Control Registry, successful maintainers report high physical activity, a consistent eating pattern, breakfast, frequent self-weighing and early correction of small regains.